Sanofi (SNY) Will Outline Long-Term Roadmap; Sees Sales CAGR at 3% - 4% from 2015 -20

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. ACN
2. SPCX
3. NVDA
4. KR
5. MSTR
6. MU
7. ICE
8. RGA
9. APGE
10. ABBV

Go back to Sanofi (SNY) Will Outline Long-Term Roadmap; Sees Sales CAGR at 3% - 4% from 2015 -20

Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes

November 6, 2015 1:01 AM EST

PARIS and THE WOODLANDS, Texas, Nov. 6, 2015 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) announced today that they have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.

"This agreement with Lexicon reinforces our commitment to helping people living with diabetes," said Pascale Witz, Executive Vice President, Sanofi, who will... More

Veracyte Announces Third Quarter 2015 Financial Results

November 5, 2015 4:05 PM EST

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2015 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced financial results for the third quarter ended September 30, 2015 and provided an update on recent business progress. Revenue for the third quarter of 2015 was $12.3 million, an increase of 25%, compared to $9.8 million for the third quarter of 2014. Afirma Gene Expression Classifier (GEC) test volume grew to 5,034 tests, an increase of 46%, compared to the same period in 2014.

"We experienced robust growth in our Afirma business, driven in... More